Abstract：【Objective】 To explore the clinical efficacy of the GS regimen (gemcitabine combined with tegafur) and PD1 immunotherapy combined with probiotics in patients after pancreatic cancer resection.【Methods】 Eighty patients who underwent pancreatic cancer resection were randomly divided into two groups, A and B, with 40 cases in each group. Group B received the GS regimen combined with PD1 immunotherapy, while Group A received the same treatment as Group B, but with the addition of probiotics. The clinical efficacy, pre-treatment and post-treatment inflammatory indicators [neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR)], NK cells and T cell subgroups (CD3+, CD4+), tumor markers [carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125)], and adverse reactions were compared between the two groups.【Results】 The total effective rate of Group A was 72.50%, which was higher than Group B's 50.00% (P<0.05). After treatment, NLR, SII, and PLR decreased in both groups (P< 0.05), with Group A having significantly lower values than Group B (P< 0.05). Tumor markers (CA19-9, CEA, CA125) also decreased in both groups after treatment (P< 0.05), with Group A showing lower levels than Group B (P< 0.05). NK cells, CD3+, and CD4+ levels increased in both groups (P< 0.05), with Group A showing higher values than Group B (P< 0.05). The total incidence of adverse reactions in Group A was 30.00%, which was lower than Group B's 55.00% (P< 0.05).【Conclusion】 The GS regimen combined with PD1 immunotherapy and probiotics can improve immune function, lower tumor marker levels, and reduce the incidence of adverse reactions in patients after pancreatic cancer resection.
黄安文, 姚礼, 吴金秀, 汪加宽, 焦成文, 杨云飞, 肖怀文. GS方案、PD1免疫疗法联合益生菌治疗胰腺癌根治术后患者的临床疗效*[J]. 医学临床研究, 2025, 42(3): 373-375.
HUANG Anwen, YAO Li, WU Jinxiu, et al. Clinical Efficacy of GS Regimen and PD1 Immunotherapy Combined with Probiotics in Patients after Pancreatic Cancer Resection. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 373-375.
2025, Vol. 42 
